Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02292758
Title Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Academic and Community Cancer Research United
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Mayo Clinic in Arizona Scottsdale Arizona 85259 United States Details
Saint Luke's Mountain States Tumor Institute Boise Idaho 83712 United States Details
Siouxland Regional Cancer Center Sioux City Iowa 51101 United States Details
Cancer Center of Kansas - Wichita Wichita Kansas 67214 United States Details
Ochsner Medical Center Jefferson New Orleans Louisiana 70121 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Michigan Cancer Research Consortium NCORP Ann Arbor Michigan 48106 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
Heartland Regional Medical Center Saint Joseph Missouri 64507 United States Details
Missouri Baptist Medical Center Saint Louis Missouri 63131 United States Details
New Hampshire Oncology Hematology PA-Hooksett Hooksett New Hampshire 03106 United States Details
State University of New York Upstate Medical University Syracuse New York 13210 United States Details
Saint Vincent Regional Cancer Center CCOP Green Bay Wisconsin 54301 United States Details
*Shaded cells indicate that there was no data available from for the field